Adjuvant therapy for stage I and II non-small cell lung cancer

The ideal adjuvant program should utilize an effective chemotherapeutic drug (or drug combination) at a maximally tolerated dose for a sufficient time to eradicate all micrometastases. Currently, no such "ideal" program has been identified. Additionally, the optimal timing of a multimodal program has not yet been established (i.e., chemotherapy followed by radiotherapy, or vice versa, or concurrent radiotherapy and chemotherapy). Adjuvant therapy at this time for stage I or II NSCLC should be considered investigational and limited to clinical trials.